Novel ocular toxicity associated with fibroblast growth factor receptor inhibitors in cancer treatment: Observational case series

Session Details

Session Title: Free Paper Session 18: New Drug & Treatment Technology

Session Date/Time: Saturday 09/09/2017 | 14:30-16:00

Paper Time: 15:30

Venue: Room 120

First Author: : D.Velazquez Villoria SPAIN

Co Author(s): :    A. Azaro   J. Rodon   D. Kyriakou   J. Garcia-Arumi   M. Zapata Vitori                 

Abstract Details


To report an observational case series of bilateral subfoveal neurosensory retinal detachment in patients with metastatic cancer undergoing chemotherapy with fibroblast growth factor receptor (FGFR) inhibitors.


Observational case series


Five patients with advanced cancer received selected pan-FGFR inhibitors as single chemotherapy in the framework of a dose finding study and a phase I and phase II clinical studies. In all cases, subfoveal neurosensory retinal detachment was diagnosed. Ophthalmic examination included visual acuity, applanation tonometry, slit lamp examination, indirect ophthalmoscopy, digital colour fundus photography, visual field, swept-source optical coherence tomography (SS-OCT), and OCT-Angiography (OCT-A) in selected cases


SS-OCT showed subfoveal neuroretinal detachment soon after treatment induction with FGFR inhibitors. Lesions were asymptomatic with a tendency to persist at follow-up without improvement. Complete resolution of subretinal fluid was only observed two patients after a two-level dose reduction and after 4 weeks of stopping mediation, respectively. In the remaining three patients, subfoveal neuroretinal detachment showed small fluctuations at follow-up visits. Permanent sequelae did not develop and none of the patients was withdrawn from clinical studies because of ocular toxicity.


Detailed characteristics of subfoveal neurosensory retinal detachment associated with FGFR inhibitor use for metastatic cancer are reported for the first time. Isolated subfoveal lesions and longer persistence of subretinal fluid are differential features from ocular toxicity associated with mitogen-activated protein kinase kinase inhibitors

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy